-
Imprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis
Thursday, October 19, 2017 - 7:50am | 569Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) announced Thursday the release of a 99-cent alternative to Allergan PLC Ordinary Shares (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease. According to Imprimis, Restasis lacks generic competition despite a...